This study is looking at a new way to manage a common viral infection called cytomegalovirus (CMV) in people who have had a lung transplant. Researchers want to see if using a lab test called the Cytomegalovirus T Cell Immunity Panel (CMV-TCIP) can safely help doctors decide how long you need to take valganciclovir, a medicine that prevents CMV infections. The goal is to potentially shorten the time you need to take valganciclovir. You can join if you are 18 to 99 years old, have had a lung transplant at NYU Langone Health, and already have CMV immunity. The main goal is to see how many people remain free of CMV infection for up to 12 months after transplant. The study is currently unclear about its recruitment status.

Study design

This is an interventional study with a planned enrollment of 50 participants. It will evaluate the use of a device and a diagnostic test alongside standard medication.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for CMV infection for up to 12 months after their transplant.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.